To evaluate the safety of SPH7854 in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
111
West China Second University Hospital, Sichuan University
Chengdu, China
RECRUITINGIncidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Approximately 2 years
PK(Pharmacokinetics):Tmax
Time to peak plasma concentration (Tmax)
Time frame: Approximately 2 years
PK(Pharmacokinetics):Cmax
Maximum serum concentration(Cmax)
Time frame: Approximately 2 years
PK(Pharmacokinetics):AUC
Area under the plasma concentration versus time curve (AUC)
Time frame: Approximately 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.